Clinical Trial Categories
Lymphoma Trials
Trial ID 21346
NCT02635672clinicaltrials.gov ID
USOR ID: 21346
Phase I
An Open-Label, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics and Maximum Tolerated Dose of VIP152 (BAY 1251152) as monotherapy or in combination with KEYTRUDA® (pembrolizumab) in Subjects with Advanced Cancer
Trial ID 20289
NCT04254107clinicaltrials.gov ID
USOR ID: 20289
Phase I
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies
Trial ID 11282
NCT01716806clinicaltrials.gov ID
USOR ID: 11282
Phase II
A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above
Trial ID 18263
NCT04116437clinicaltrials.gov ID
USOR ID: 18263
Phase II
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib
Trial ID 20133
NCT04824092clinicaltrials.gov ID
USOR ID: 20133
Phase III
A Phase III, multicenter, open-label, randomized trial comparing the efficacy and safety of Tafasitamab plus Lenalidomide in addition to R-CHOP versus R-CHOP in high-risk patients with previously untreated Diffuse Large B-Cell Lymphoma
Trial ID 21195
NCT04981795clinicaltrials.gov ID
USOR ID: 21195
Phase N/A
Prospective multicenter observational study of patients with relapsed or refractory diffuse large B-cell lymphoma starting second- or third-line therapy and not receiving autologous stem cell transplant
Trial ID
NCT05471843clinicaltrials.gov ID
Phase N/A
Trial ID 19109
NCT03460977clinicaltrials.gov ID
USOR ID: 19109
Phase I
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Trial ID
NCT02922764clinicaltrials.gov ID
Phase I
